While speaking at the ‘Rescue the Republic’ event in Washington D.C. on Sunday, Dr. Robert Malone issued a warning from his recent trip to Japan.

“I just came back from Tokyo where they had a 30,000 person rally because they’re about to deploy self-replicating RNA vaccines. Japan is being used as the guinea pigs for the world for this new technology. The Japanese people are calling this the third atomic bomb,” Malone said.

“This is being deployed in a cooperative agreement between a US company, Arcturus, a Canadian company, I’m sorry, an Australian company called CSL and a Japanese company,” he continued.

“Now the CEO of the Japanese company recently gave a press conference. What did he say? He said anybody that is spreading misinformation, we’re going to go after him legally, we’re going to try to have them jailed. If you say anything against their self-replicating RNA vaccine technology that’s never been rigorously tested, we don’t know if it’s going to infect other people. We don’t know if it’s going to spread. We know it’s going to replicate. We don’t know if it’s going to get into the brain of the elders in Japan,” Malone explained.

“But we do know that if we say anything about these concerns, the CEO is going to come after us and try to put us in jail. That’s the new world order. That’s what we’re coming into. That’s what they want to implement on us,” he continued.

“They want to shut us down. They want to prevent us from speaking. They want to completely control the narrative and they want to be able to deploy psychological warfare on all of you to control you, to train you, to respond to the fear narratives about avian influenza and monkeypox and whatever it is they want to deploy next in order to control you, in order to teach you to shut up, sit down, stay in your homes, and do what you’re told. Now I’m not okay with that, I don’t think you’re okay with that, and I hope that you join all of us in fighting this new tyranny,” he added.

WATCH:

“Global biotechnology leader CSL and sa-mRNA pioneer Arcturus Therapeutics today announced that Japan’s Ministry of Health, Labor and Welfare (MHLWs) granted approval and authorization for their updated self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, KOSTAIVE®. The updated vaccine is targeted to protect against the JN.1 lineage of Omicron subvariants for adults 18 years of age and older,” CSL announced last month.

Japan’s Ministry of Health, Labour and Welfare approved CSL and Arcturus Therapeutics’ self-amplifying mRNA COVID-19 vaccine in November 2023.

“The updated sa-mRNA COVID-19 vaccine is tailored to protect against the JN.1 lineage of Omicron subvariants,” CSL stated.

“Meiji Seika Pharma, CSL’s exclusive partner in Japan, will begin vaccine distribution in time for the October COVID-19 vaccination campaign,” it added.

Per CSL:

CSL’s exclusive partner in Japan, Meiji Seika Pharma, will begin distributing the updated vaccine in time for the October COVID-19 vaccination campaign, marking the world’s first commercially available sa-mRNA COVID-19 vaccine for adults 18 and older.

In May 2024, a Japanese health ministry panel recommended that COVID-19 vaccines be updated to target the JN.1 lineage of Omicron subvariants for the 2024/2025 national immunization program. This aligns with recent recommendations from the World Health Organization.

“We are pleased to receive the updated approval from Japan’s Ministry of Health, Labor and Welfare, and remain on track to distribute KOSTAIVE® in time for the October COVID-19 vaccination campaign,” said Emmanuelle Lecomte-Brisset, Senior Vice President and Head of Global Regulatory Affairs, CSL. “We look forward to introducing KOSTAIVE® in Japan as a safe, tolerable and more durable option in protecting against COVID-19.”

“We believe KOSTAIVE® has the potential to change the paradigm for COVID-19 vaccines in Japan,” said Jonathan Edelman, M.D., Senior Vice President, Vaccines Innovation Unit, CSL. “Today’s approval further demonstrates CSL’s promise to pursue, develop and deliver new innovative treatment options to protect public health.”

The approval is based on clinical evidence supporting the safety and effectiveness of CSL and Arcturus Therapeutics’ sa-mRNA COVID-19 vaccine, including published data demonstrating superior immunogenicity to Omicron BA 4/5 compared to a conventional mRNA COVID-19 vaccine booster and follow-up data demonstrating duration of immunity lasting up to one year.

“We are pleased that our sa-mRNA technology will be available to vaccinate people in Japan against COVID-19, which remains an ongoing risk to public health around the world,” said Joseph Payne, Chief Executive Officer of Arcturus Therapeutics. “We look forward to continuing to work with CSL and regulators to explore the development of KOSTAIVE® in additional countries.”

 

Join The Conversation. Leave a Comment.


We have no tolerance for comments containing violence, racism, profanity, vulgarity, doxing, or discourteous behavior. If a comment is spam, instead of replying to it please click the ∨ icon below and to the right of that comment. Thank you for partnering with us to maintain fruitful conversation.